Cryoport, Inc. (NASDAQ:CYRX – Get Free Report) CEO Jerrell Shelton sold 2,631 shares of the company’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $17.54, for a total value of $46,147.74. Following the completion of the transaction, the chief executive officer now directly owns 692,182 shares in the company, valued at $12,140,872.28. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Jerrell Shelton also recently made the following trade(s):
- On Monday, March 11th, Jerrell Shelton sold 3,723 shares of Cryoport stock. The stock was sold at an average price of $16.35, for a total value of $60,871.05.
- On Friday, March 15th, Jerrell Shelton sold 57,039 shares of Cryoport stock. The stock was sold at an average price of $15.30, for a total value of $872,696.70.
Cryoport Price Performance
Shares of NASDAQ:CYRX opened at $18.12 on Thursday. The business has a 50 day moving average price of $15.95 and a 200 day moving average price of $14.37. Cryoport, Inc. has a twelve month low of $9.00 and a twelve month high of $24.30. The company has a market cap of $887.52 million, a price-to-earnings ratio of -8.24 and a beta of 1.61. The company has a quick ratio of 11.16, a current ratio of 11.73 and a debt-to-equity ratio of 0.82.
Institutional Trading of Cryoport
Analyst Ratings Changes
Several analysts have recently issued reports on CYRX shares. Needham & Company LLC decreased their price target on Cryoport from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, March 13th. Stephens reiterated an “equal weight” rating and set a $17.00 price target on shares of Cryoport in a research note on Wednesday, March 13th. Finally, UBS Group upped their price target on Cryoport from $14.50 to $17.00 and gave the stock a “neutral” rating in a research note on Friday, March 15th. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Cryoport has a consensus rating of “Hold” and a consensus price target of $18.29.
Read Our Latest Stock Analysis on Cryoport
About Cryoport
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
Featured Articles
- Five stocks we like better than Cryoport
- What is Put Option Volume?
- Best Bear Market Funds: Top 3 Investment Options to Consider
- What is a Bond Market Holiday? How to Invest and Trade
- Is DraftKings A Good Bet Ahead of Q1 Earnings?
- 10 Best Airline Stocks to Buy
- Mid-Cap Stocks to Outperform the Market This Cycle
Receive News & Ratings for Cryoport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryoport and related companies with MarketBeat.com's FREE daily email newsletter.